{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:31:18Z","timestamp":1795095078308,"version":"4.10.2"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126469","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T02:25:27Z","timestamp":1731032727000},"page":"126469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"P1","title":["Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4\u00a0years following a primary series and safety and immunogenicity of a booster dose"],"prefix":"10.1016","volume":"43","author":[{"given":"James","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Drazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Moughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lefteris","family":"Zolotas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Maansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Beeslaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126469_bb0005","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126469_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.126469_bb0015","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268823000328","article-title":"Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review","volume":"151","author":"Pardo de Santayana","year":"2023","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2024.126469_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.126469_bb0025","first-page":"1521","volume":"8","author":"Pizza","year":"2020","journal-title":"Vaccines against meningococcal diseases Microorganisms"},{"key":"10.1016\/j.vaccine.2024.126469_bb0030","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1093\/cid\/ciaa1636","article-title":"Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126469_bb0035","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","article-title":"Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study","volume":"6","author":"Campbell","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2024.126469_bb0040","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","article-title":"Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States","volume":"174","author":"Mbaeyi","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2024.126469_bb0045","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/cid\/ciab791","article-title":"Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study","volume":"74","author":"Ohm","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126469_bb0050","doi-asserted-by":"crossref","first-page":"2251825","DOI":"10.1080\/21645515.2023.2251825","article-title":"Real-world impact and effectiveness of MenACWY-TT","volume":"19","author":"Villena","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126469_bb0055","series-title":"Penbraya (meningococcal groups A, B, C, W, and Y vaccine). Full prescribing information","year":"2023"},{"key":"10.1016\/j.vaccine.2024.126469_bb0060","author":"Pfizer Inc"},{"key":"10.1016\/j.vaccine.2024.126469_bb0065","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1473-3099(23)00191-3","article-title":"Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial","volume":"23","author":"Peterson","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126469_bb0070","author":"US Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2024.126469_bb0075","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s40121-022-00609-9","article-title":"Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review","volume":"11","author":"Marshall","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2024.126469_bb0080","author":"European Centre for Disease Prevention and Control"},{"key":"10.1016\/j.vaccine.2024.126469_bb0090","author":"US Centers for Disease Control and Prevention"},{"key":"10.1016\/j.vaccine.2024.126469_bb0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jpids\/piz024","article-title":"US college students are at increased risk for serogroup B meningococcal disease","volume":"9","author":"Marshall","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2024.126469_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2018-0343","article-title":"Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence","volume":"14","author":"Findlow","year":"2019","journal-title":"Future Microbiol"},{"key":"10.1016\/j.vaccine.2024.126469_bb0105","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","article-title":"Ten-year antibody persistence and booster response to MenACWY-TT vaccine after primary vaccination at 1-10 years of age","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126469_bb0110","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1016\/j.vaccine.2021.06.005","article-title":"Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine MenB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months","volume":"39","author":"Ostergaard","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126469_bb0115","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.vaccine.2018.11.073","article-title":"Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: a phase 3 extension study in adolescents","volume":"37","author":"Vesikari","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126469_bb0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.vaccine.2021.11.053","article-title":"A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults","volume":"40","author":"Drazan","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126469_bb0125","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14760584.2018.1483726","article-title":"From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine","volume":"17","author":"Perez","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126469_bb0130","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126469_bb0135","author":"US Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2024.126469_bb0145","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1093\/cid\/ciaa1733","article-title":"Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and meta-analysis","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126469_bb0150","doi-asserted-by":"crossref","unstructured":"Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect 2022;28:1649.e1-.e8. doi:https:\/\/doi.org\/10.1016\/j.cmi.2022.07.004.","DOI":"10.1016\/j.cmi.2022.07.004"},{"key":"10.1016\/j.vaccine.2024.126469_bb0155","doi-asserted-by":"crossref","first-page":"912","DOI":"10.15585\/mmwr.mm7234a3","article-title":"Vaccination coverage among adolescents aged 13-17 years - National Immunization Survey-Teen, United States, 2022","volume":"72","author":"Pingali","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.126469_bb0160","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/INF.0000000000003033","article-title":"Implementation experience with meningococcal serogroup B vaccines in the United States: impact of a nonroutine recommendation","volume":"40","author":"Fergie","year":"2021","journal-title":"Pediatr Infect Dis J"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2026.128884","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:28:51Z","timestamp":1786483731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24011514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"alternative-id":["S0264410X24011514"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126469","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4\u00a0years following a primary series and safety and immunogenicity of a booster dose","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Pfizer Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126469"}}